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Development of a human 
vasopressin V1a-receptor antagonist 
from an evolutionary-related insect 
neuropeptide
Maria Giulia Di Giglio1, Markus Muttenthaler2, Kasper Harpsøe3, Zita Liutkeviciute1, 
Peter Keov4, Thomas Eder5,6,†, Thomas Rattei6, Sarah Arrowsmith7, Susan Wray7, Ales Marek8, 
Tomas Elbert8, Paul F. Alewood2, David E. Gloriam3 & Christian W. Gruber1,4
Characterisation of G protein-coupled receptors (GPCR) relies on the availability of a toolbox of ligands 
that selectively modulate different functional states of the receptors. To uncover such molecules, we 
explored a unique strategy for ligand discovery that takes advantage of the evolutionary conservation 
of the 600-million-year-old oxytocin/vasopressin signalling system. We isolated the insect oxytocin/
vasopressin orthologue inotocin from the black garden ant (Lasius niger), identified and cloned its 
cognate receptor and determined its pharmacological properties on the insect and human oxytocin/
vasopressin receptors. Subsequently, we identified a functional dichotomy: inotocin activated the 
insect inotocin and the human vasopressin V1b receptors, but inhibited the human V1aR. Replacement of 
Arg8 of inotocin by D-Arg8 led to a potent, stable and competitive V1aR-antagonist ([D-Arg8]-inotocin) 
with a 3,000-fold binding selectivity for the human V1aR over the other three subtypes, OTR, V1bR and 
V2R. The Arg8/D-Arg8 ligand-pair was further investigated to gain novel insights into the oxytocin/
vasopressin peptide-receptor interaction, which led to the identification of key residues of the receptors 
that are important for ligand functionality and selectivity. These observations could play an important 
role for development of oxytocin/vasopressin receptor modulators that would enable clear distinction 
of the physiological and pathological responses of the individual receptor subtypes.
G protein-coupled receptors (GPCRs) represent one of the largest families of membrane bound proteins in the 
human genome1,2. They form attractive drug targets as they play a crucial role in the regulation of physiological 
signalling systems and are accessible at the cell surface3. In recent years, the field of GPCR research has evolved 
at great pace; advances in structural characterisation of several GPCRs has led to detailed analyses of their phar-
macological properties4,5. Such studies rely heavily on the availability of a chemical toolbox of compounds6 that 
selectively stabilize conformational states of GPCRs. The alliance between chemistry and pharmacology has led 
to astonishing breakthroughs in understanding ligand-receptor interactions and the development of valuable 
therapeutics.
The oxytocin/vasopressin signalling system constitutes one of the most complex and important neuroendocrine 
systems in humans. There are four known receptor subtypes, the oxytocin receptor (OTR) and vasopressin receptor 
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isoforms V1aR, V1bR and V2R7. These receptors belong to the largest subclass of the rhodopsin-β adrenergic recep-
tor family (class A)8 and are activated by the two endogenous peptide ligands oxytocin and arginine-vasopressin. 
Despite the lack of a crystal structure, several strategies have attempted to identify and develop receptor probes to 
study the structure-activity relationships and molecular signalling properties of these GPCRs (summarized in refs 
9,10). Nonetheless, the structural homology of endogenous peptides and receptors is a major inconvenience and 
hampers the development of powerful molecular probes9. Although the oxytocin/vasopressin signalling system is 
linked to a diverse range of high-profile disorders including preterm labour, cancer, pain, autism, anxiety, stress, 
depression, and cardiovascular diseases7,11,12, there is still a lack of selective receptor agonists and antagonists, which 
limits our ability to characterize the physiological and pathological function of each receptor subtype9,13.
In humans and other mammalian species, oxytocin and vasopressin signalling displays an extensive repertoire 
of peripheral physiological functions, including uterine smooth muscle contraction during parturition, ejacu-
lation, milk let-down, vasoconstriction and osmoregulation (summarized in ref. 14). Centrally, this neuropep-
tidergic system has been implicated in memory and learning, social cognition and aggressive behaviour15–18. 
Oxytocin (CYIQNCPLG-NH2) and arginine-vasopressin (CYFQNCPRG-NH2) are cyclic nonapeptides contain-
ing a disulfide bond between Cys-residues in positions 1 and 6, differing only in two positions in most mammals 
(residues 3 and 8)9. Oxytocin- and vasopressin-like peptides have been identified in all vertebrate animals, as well 
as in some invertebrate species19. These peptides are evolutionarily highly conserved and functionally related19,20. 
The arthropod orthologue of oxytocin and vasopressin, called inotocin (CLITNCPRG-NH2)21,22, also exhibits a 
high degree of structural conservation offering a unique opportunity to probe structure/function-relationships 
of the human oxytocin and vasopressin receptors to increase our molecular understanding of these GPCRs23.
In the present study, we isolated, cloned and characterized the inotocin receptor with its cognate ligand ino-
tocin from the black garden ant (Lasius niger) and exploited its evolutionary relationship and structural sim-
ilarity to the human vasopressin V1a and V1b receptors. Our approach aimed at demonstrating that exploring 
a highly conserved and widely distributed signalling system such as the oxytocin/vasopressin system is a good 
strategy for the discovery and development of much needed selective probes for the study of the four human 
receptor subtypes. To validate the pharmacological tools, we determined the molecular properties of the endoge-
nous ant ligand-receptor pair, in comparison to the previously identified inotocin receptor of the red flour beetle 
(Tribolium castaneum). Based on the molecular conservation of the insect and human signalling systems, we con-
ducted in vitro pharmacological studies of the insect inotocin at the four human oxytocin/vasopressin receptors. 
Due to the observed binding and activation profiles of the insect ligand, we probed the structure-activity rela-
tionship by replacing Arg8 of inotocin with its corresponding D-stereoisomer to investigate how this amino acid 
substitution influences ligand binding and selectivity. This approach successfully yielded a potent, selective and 
very stable antagonist of the human V1aR, which was validated in functionally-relevant ex vivo uterine contrac-
tion studies. These probes furthermore provided novel insights into the molecular binding features and evolution 
of the ligand-receptor pairs of the oxytocin/vasopressin signalling system.
Results
Transcriptome analysis and discovery of the inotocin pre-prohormone and partial receptor 
sequences from L. niger. As previously published, insect neuropeptides have been discovered by 
genome-mining21, but it is challenging to derive full-length receptor sequences due to the size of the coding 
sequences and the presence of multiple introns. Therefore, we aimed to identify the inotocin precursor and its recep-
tor in L. niger by transcriptome analysis. To reconstruct the transcriptome, we sequenced L. niger cDNA via paired 
end Illumina HiSeq 2000 Technology. The initially obtained 85,112,874 raw sequence read pairs were quality and 
length filtered and the remaining 90.1% high quality pairs were screened for rRNA reads, which led to the removal 
of 6.8% of the sequence read pairs. Hence, de-novo assembly for the reconstruction of the L. niger transcriptome 
was initiated with 71,435,903 of high quality mRNA read pairs. This resulted in 564.8 megabases distributed over 
380,930 contigs with a N50 of 3,308 base pairs (bp). These contigs represent different L. niger transcripts and iso-
forms. We identified 99.6% of a defined set of highly conserved genes. This near complete transcriptome was subject 
to a sequence similarity search using several insect inotocin precursor and receptor sequences as queries. It resulted 
in 125 hits for the receptor and two significant hits for the precursor namely the contigs comp45093_c0_seq1 and 
comp45093_c0_seq2. These sequences represent the transcribed sequences of the inotocin precursor and receptor 
of L. niger. The top precursor hit exhibited a similar domain structure as compared to the human proteins (Fig. 1A). 
The second precursor hit was discarded as it was considered an artefact. The 125 receptor hits represent different 
isoforms and assembly artefacts of the most homologous receptors in the assembly. To verify that we have identified 
the inotocin receptor of L. niger, we reconstructed the phylogenetic relationship of the most relevant hits (multiple 
near identical contigs with different length per main hit). The resulting phylogenetic tree confirmed that we indeed 
detected the inotocin receptor of L. niger (Supplementary Fig. 1). The verified receptor and precursor sequences were 
used as templates for molecular cloning.
Molecular cloning and characterization of the inotocin signalling system. The full length amplifi-
cation product corresponding to the novel ant precursor was directly sequenced, and the full length amplification 
product corresponding to the novel ant receptor was cloned into a plasmid and its sequence confirmed by DNA 
sequencing. Multiple sequence alignments of precursor (Fig. 1B) and receptor (Supplementary Fig. 2) provided 
further evidence of the molecular similarity of insect and human oxytocin/vasopressin-like receptors. For func-
tional characterization of the inotocin peptide-receptor system, the peptide inotocin was chemically synthesized 
and the cDNA encoding the L. niger inotocin receptor was cloned into a pEGFP plasmid for transient expression 
in mammalian cells. For pharmacological validation of the ant signalling system we determined affinity and 
potency of inotocin to its cognate receptor from L. niger and compared the data to the known ligand-receptor 
pair from T. castaneum. The affinity for the inotocin peptides was determined via competitive radioligand binding 
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experiments (Fig. 2A) on membrane preparations of mammalian cells transiently expressing these receptors. 
Inotocin displaced its tritiated analogue with a Ki of 6 and 10 nM at the ant and beetle receptors, respectively 
(Table 1). The functional Gq-coupled receptor response was monitored by detection of the production and accu-
mulation of inositol monophosphate (IP1), a downstream metabolite of D-myo-inositol 1,4,5-trisphosphate (IP3), 
following the activation of phospholipase C (Fig. 2B). The endogenous ligand inotocin is able to activate the ant 
receptor at low picomolar concentrations with an EC50 value of 22 pM, and the beetle receptor was activated with 
a potency of 350 pM (Table 2), in agreement with previous published data24.
Pharmacological characterization of inotocin at the human oxytocin and vasopressin recep-
tors. Based on the structural homology of the inotocin peptide, we pursued the pharmacological characteri-
zation of the endogenous inotocin on human OTR, V1aR, V1bR and V2R receptors. We determined the affinity of 
inotocin peptide to the human receptors (Fig. 2C and Table 1) and estimated the ability of this insect peptide to 
elicit a concentration-dependent functional response (Fig. 2D and Table 2). Inotocin exhibited nanomolar affinity 
to the human V1aR (Ki = 11 nM), V1bR (Ki = 12 nM) and OTR (Ki = 62 nM), but does not appear to displace [3H] 
vasopressin from the human V2R at concentrations < 10 μ M (Table 1). Interestingly, the insect ligand is a full ago-
nist at the human V1bR (EC50 = 56 nM), but does not activate the V1aR or OTR at a detectable level (EC50 > 10 μ M) 
(Table 2). Despite being unable to displace [3H] vasopressin at the human V2R (Table 1), inotocin exhibited partial 
activation of this receptor with an EC50 > 1.5 μ M, possibly through direct allosteric agonism.
Pharmacological characterization of the modified ligand [D-Arg8]-inotocin at the human 
oxytocin and vasopressin receptors. Previous studies indicated that the Arg in position 8 of vaso-
pressin mediates ligand functionality and receptor selectivity in the human oxytocin/vasopressin family25–28. 
Additionally, the proline-arginine site is easily cleaved by enzymes such as trypsin29 and forms a well-known posi-
tion to improve metabolic stability through introducing D-Arg instead of L-Arg30. Having in mind harnessing 
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Lasius niger prepro-INT
Tribolium castaneum prepro-INT
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Lasius niger prepro-INT
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Homo sapiens prepro-OT
Homo sapiens prepro-AVP
Lasius niger prepro-INT
Tribolium castaneum prepro-INT
Homo sapiens prepro-OT
Homo sapiens prepro-AVP
B
Figure 1. Neuropeptide prepro-hormones of humans and insects. (A) Oxytocin (OT), arginine-vasopressin 
(AVP) and inotocin (INT) peptide precursors share a similar structure with signal peptide (grey), GKR 
processing signal (black), neurophysin domain (white) and copeptin (dark grey, in the case of vasopressin). 
(B) Multiple sequence alignment of the precursor sequences of the black garden ant (L. niger) and the red flour 
beetle (T. castaneum) were compared to human oxytocin and vasopressin. Alignment was performed with 
Clustal Omega and homologous regions were highlighted in Boxshade representation. The mature peptide 
domains are coloured in red.
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Figure 2. Receptor pharmacology of inotocin on inotocin and human oxytocin/vasopressin receptors.  
(A) Concentration-dependent displacement of [3H] inotocin by inotocin at inotocin receptors (INTR) from 
Lasius niger ( ) and Tribolium castaneum ( ) (n = 4). (B) Concentration-dependent accumulation of 
intracellular IP1 by inotocin at INTR from L. niger (n = 9) and T. castaneum (n = 4). (C) Concentration-
dependent displacement binding of inotocin on human OTR ( ), V1aR ( ), V1bR ( ) and V2R ( ) (n = 4). (D) 
Concentration-dependent second messenger production by inotocin at human OTR, V1aR, V1bR and V2R 
(n ≥ 3). Specific binding was calculated by subtracting the non-specific from the total bound and normalised to 
100%. A full description of radioligand and membrane concentrations is reported in the Methods section. 
Receptor activation was measured by IP1 assays for the Gq-coupled receptors (human OTR, V1aR, V1bR) and 
luciferase reporter assay with specific CRE response element for the Gs-coupled human V2R, as described in 
Methods. Each data point was normalized to percentage of maximal activation, detected at the highest 
endogenous ligand concentration, being inotocin for inotocin receptor, vasopressin for human V1aR, V1bR, V2R 
and oxytocin for human OTR. Data is shown as mean ± SEM and fitted by nonlinear regression (sigmoidal, 
three-parameters, Hill slope of 1).
Peptide Sequence
inotocin R  
(L. niger)
inotocin R  
(T. castaneum)
human 
V1aR
human 
V1bR
human 
V2R human OTR
inotocin CLITNCPRG* 6.0 ± 2.8 11 ± 3.9 11 ± 4.4 12 ± 6.5 > 105 62 ± 37
vasopressin CYFQNCPRG* > 105 > 105 2.6 ± 0.2 1.2 ± 0.6 4.2 ± 1.3 1.8 ± 0.5†
[D-Arg8]-inotocin CLITNCPrG* 61 ± 10# 217 ± 77 1.3 ± 0.4 > 105 > 105 > 4000
Table 1.  Affinity (Ki in nM) of inotocin, [D-Arg8]-inotocin and vasopressin on insect and human 
receptors. *C-terminal amide; †value is for oxytocin at the oxytocin receptor; affinity (Ki) data are indicated as 
mean ± SEM from at least 3 independent experiments (except #n = 2); Ki values were calculated from IC50 values 
according to Cheng and Prusoff65, assuming Kd values of 0.6 nM for V1aR, 0.1 nM for V1bR, 1.2 nM for V2R and 
1.5 nM for OTR. Kd values of inotocin receptors were determined from saturation binding experiments to be 
0.9 nM (L. niger) and 2.7 nM (T. castaneum).
Peptide Sequence
inotocin R  
(L. niger)
inotocin R  
(T. castaneum) human V1aR
human 
V1bR
human 
V2R
human 
OTR
inotocin CLITNCPRG* 0.022 ± 0.006 0.35 ± 0.05 > 105 56 ± 9.7 > 1500 > 105
vasopressin CYFQNCPRG* > 105 > 105 0.13 ± 0.02 0.6 ± 0.07 175 ± 76 41 ± 39
[D-Arg8]-inotocin CLITNCPrG* 1.2 ± 0.7 12 ± 3.5 > 105 > 105 164 ± 26 > 105
Table 2.  Potency (EC50 in nM) of inotocin, [D-Arg8]-inotocin and vasopressin on insect and human 
receptors. *C-terminal amide; functional receptor activation (EC50) is indicated as mean ± SEM from at least 3 
independent experiments.
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the insect system to guide the development of novel and stable probes to study human GPCRs, we synthesised 
[D-Arg8]-inotocin and characterized it pharmacologically at the insect and human receptors (Tables 1 and 2). 
[D-Arg8]-inotocin is a partial agonist (apparent maximum response Emax ~80%) at the inotocin receptors from 
L. niger and T. castaneum with a potency (EC50) of 1.2 and 12 nM, respectively, and an affinity (Ki) of 61 and 217 nM, 
respectively (Supplementary Fig. 3). Interestingly, the D-Arg8 modification resulted in a selectivity profile switch at 
the human receptor subtypes; [D-Arg8]-inotocin improved its binding affinity at human V1aR compared to inoto-
cin (Ki = 1.3 nM; Table 2 and Supplementary Fig. 3), but did not exhibit any significant displacement at the human 
OT, V1b, V2 receptor isoforms (Ki > 4 μ M) (Table 2 and Supplementary Fig. 3). [D-Arg8]-inotocin was not able to 
evoke a functional IP1 response at the human OT, V1a or V1b receptors (EC50 > 10 μ M), yet retained a low potency 
response at human V2R (EC50 of 164 nM) possibly by direct allosteric agonism as observed with inotocin (Table 2 
and Supplementary Fig. 3).
Competitive antagonism of [D-Arg8]-inotocin at the human V1aR. To investigate the inhibitory 
mechanism of [D-Arg8]-inotocin further, we quantified the concentration-dependent activation of the recep-
tor by the endogenous ligand vasopressin in the absence and presence of a set of constant concentrations of 
[D-Arg8]-inotocin (30, 100, 300 and 1000 nM, respectively). Typical for a competitive antagonist, we observed a 
dextral displacement of the concentration-response curves of vasopressin, with no change in the Emax (Fig. 3B). 
To confirm a competitive antagonist action of [D-Arg8]-inotocin at the human V1aR, we performed Schild regres-
sion analysis. The regression of the concentration-ratio, which is a measure of the potency of a drug and the con-
centration of antagonist [D-Arg8]-inotocin was linear and had a slope of unity, indicating that the antagonism is 
indeed competitive. [D-Arg8]-inotocin is a competitive inhibitor of the human V1aR with a gain of approximately 
three orders of magnitude selectivity in affinity over the other oxytocin/vasopressin receptors. The pA2 value of 
this competitive antagonism has been calculated as 7.8 (Fig. 3B), corresponding to a functional affinity of approx-
imately 16 nM.
Identification of receptor residues responsible for the pharmacological profile of [D-Arg8]- 
inotocin. Following the characterization of [D-Arg8]-inotocin as a subtype selective vasopressin V1a-receptor 
Figure 3. [D-Arg8]-inotocin is a competitive antagonist at the human V1a receptor. (A) Concentration-
dependent displacement of [3H] vasopressin in membrane preparations expressing the human V1aR by either 
[D-Arg8]-inotocin or vasopressin (n = 4). Specific binding was calculated by subtraction of non-specific 
binding from total binding and normalized to the percentage (%) of maximal binding. (B) Concentration-
response curves of vasopressin at the human V1aR in the absence and presence of varying concentrations of 
[D-Arg8]-inotocin (30, 100, 300 and 1000 nM). Fold induction of intracellular IP1 accumulation above baseline 
was normalized to the number of cells. Data were fitted by nonlinear regression (sigmoidal, slope = 1). Affinity 
constants (Ki) and potency (EC50) values for AVP and [D-Arg8]-inotocin are presented in Tables 1 and 2. Schild 
regression analysis of [D-Arg8]-inotocin at the human V1aR is shown as insert. The corresponding Schild plot 
is presented in comparison to a linear curve with a slope of 1.0 and the X-intercept of Ki for [D-Arg8]-inotocin. 
The pA2 value of 7.8 was derived as X-intercept of the Schild regression curve.
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ligand, we wanted to rationalize this effect in terms of key ligand interactions in the context of the receptor binding 
site. Analysis of sequence differences between the human vasopressin and ant/beetle inotocin receptors should pro-
vide insights into the observed differences in functional and binding selectivity. To pinpoint the amino acid positions 
in the receptors that are accessible by ligands, i.e. residues in the upper part of the transmembrane (TM) helices and 
the extracellular loop (ECL) 2 facing the common GPCR binding cavity, we constructed homology models of the six 
receptors (human OTR, V1aR, V1bR and V2R; L. niger and T. castaneum inotocin receptors) using the crystal structures 
of the μ -opioid and orexin receptors31,32 as templates. Based on these models, 43 positions with side-chains facing the 
spacious inter-helical cavity were extracted from the global sequence alignment to construct a local structure-based 
binding site alignment (Fig. 4A and Supplementary Fig. 4). This approach offers a way to identify both conserved and 
different sequence positions, which are likely to influence peptide binding, selectivity and function. The sequence simi-
larity of the binding site residues of the three human vasopressin receptors is within 74–88%, between the ant and beetle 
inotocin receptor 77%, and between the vasopressin V1a/V1b receptors and the two inotocin receptors 63%. In total, 
21 (49%) positions of the binding cavity are conserved residues with similar properties in all receptors, e.g. Glu1×35, 
Lys3×29, Glu/Asp45×49 (GPCRdb generic numbering33), which explains the binding of native inotocin to 5 out of 6 
receptors (except human V2R, where allosteric agonism was observed). Furthermore, the binding site alignment shows 
6 positions in the V1aR, i.e. Ala139(3×40), Ile192, Ser213(5×36), Met220(5×43), Ile330(7×34) and Ala334(7×38), which distin-
guish V1aR from V1bR and the inotocin receptors (Fig. 4A) and which could be responsible for the observed inactivity 
of native inotocin at V1aR while being a full agonist at V1bR (Table 2). Additionally, the 4th position in ECL2 (Ile192 
in V1aR) and position 7×38 contain an Arg and Met, respectively, in V1bR, V2R and OTR, while the corresponding 
residues in V1aR and the inotocin receptors have neutral and short side chains. This could be correlated to the lack of 
binding for [D-Arg8]-inotocin at the V1bR, V2R and OTR.
Human serum stability of [D-Arg8]-inotocin. In addition to the valuable selectivity profile at the 
human oxytocin/vasopressin receptors, [D-Arg8]-inotocin was anticipated to be significantly more stable than 
Figure 4. The selectivity of [D-Arg8]-inotocin for V1aR is conferred by a unique binding mode.  
(A) Sequence alignment of the binding site residues of the six investigated receptors, inotocin receptors L. niger 
and T. castaneum, as well as human V1aR, V1bR, V2R and OTR as defined by the receptor homology models. 
Together with the consensus sequence, the conservation score from 1–10 by physico-chemical properties72 
and “*” indicating complete identity is given below the alignment. The sequence-based residue numbers are 
according to the V1aR, while the numbers in parenthesis are generic residue numbers from the GPCR database, 
GPCRdb.org33. (B and C) Models of the inotocin/[D-Arg8]-inotocin Arg8/D-Arg8 salt bridge interactions with 
the receptor residues Glu1 ×35 and Asp45×49, respectively. V1aR is represented as cyan cartoon and sticks, 
Arg8 and D-Arg8 are represented as thick and thin white sticks, respectively, and residues from V1bR are shown 
as magenta sticks. Putative salt-bridge interactions are indicated by the dashed lines; green between Arg8 and 
V1aR, yellow between D-Arg8 and V1aR and red to Arg 175 in V1bR37.
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its lead ligand inotocin as well as vasopressin due to dismantling the recognized trypsin Pro-Arg cleavage site by 
introducing the non-natural D-Arg residue29,34. The increased stability of [D-Arg8]-inotocin was confirmed in 
human serum by reversed-phase high performance liquid chromatography (RP-HPLC) in a 24 h time-course 
experiment (Supplementary Fig. 5). Native inotocin, vasopressin and melittin were used as controls. Whilst 
vasopressin (t½ = 1.0 h), inotocin (t½ = 2.8 h) and melittin (t½ = 0.7 h) were fully degraded within 24 h, > 70% of 
[D-Arg8]-inotocin was still present after 24 h.
Concentration-dependent inhibit ion of  human myometrial  contractions by 
[D-Arg8]-inotocin. To assess the functional relevance of this novel human V1aR antagonist we tested 
[D-Arg8]-inotocin in a well-recognised ex vivo human uterine contractility model14,35. After obtaining sta-
ble contractions of prepared tissue, human myometrium was stimulated with vasopressin (0.5 nM). The 
effects of [D-Arg8]-inotocin on these contractions were then investigated and compared to the small mol-
ecule V1aR antagonist SR49059 (relcovaptan)10. Both ligands caused a concentration-dependent decrease 
in vasopressin-augmented myometrial contraction amplitude and area-under-the-curve (Fig. 5A,B). For 
[D-Arg8]-inotocin, this became significant at 10 nM for amplitude (P < 0.01) (Supplementary Fig. 6A) and 
100 nM for area-under-the-curve (P < 0.05) (Fig. 5D; Supplementary Fig. 6B). For SR49059, at 30 nM we observed 
a significant reduction in uterine contraction for both amplitude of contraction and area-under-the-curve 
(P < 0.05 and P < 0.001, respectively) (Supplementary Fig. 6C,D). Some contraction recovery was noted for 
both ligands upon washout (Fig. 5A,B). The effect of 100 nM [D-Arg8]-inotocin and SR49059 on amplitude of 
contraction and area-under-the-curve compared to the vasopressin (time-equivalent) and control activity are 
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Figure 5. Uterine contractility inhibitory effects of [D-Arg8]-inotocin. Inhibitory effect of increasing 
concentrations of (A) [D-Arg8]-inotocin ([D-Arg8]INT) and (B) the commercially-available V1aR antagonist 
SR49059 on vasopressin-augmented (0.5 nM) myometrial contractions. Contraction amplitude and area-
under-the-curve (AUC) under [D-Arg8]-inotocin treatment (100 nM) were significantly reduced (P < 0.05 
and P < 0.001, respectively) as compared to control activity. As expected, SR49059 reduced both amplitude 
of contraction and AUC significantly at 100 nM (P < 0.001). The mean amplitude of contraction and AUC 
calculated for 100 nM [D-Arg8]-inotocin, SR 49059 or vasopressin (time-equivalent), expressed as a percentage 
of control where control equals 100% are shown in C and D. Application of 100 nM [D-Arg8]-inotocin 
significantly reduced contraction amplitude by 22.9 (± 2.5%, P < 0.001) and AUC by 36.6 (± 13.1%, P < 0.05). 
SR49059 (100 nM) significantly reduced contraction amplitude and AUC by 54.8 (± 15.5%, P < 0.001) and 72.1 
(± 12.5%, P < 0.001), respectively. Contractions augmented by vasopressin (AVP) persisted without significant 
loss of amplitude or AUC for over 2 h during the time equivalent of experimental manoeuvers (C–F) and 
[D-Arg8]-inotocin has no inhibitory effect on contractions augmented with oxytocin (G). *P < 0.05, **P < 0.01, 
***P < 0.001 (n = 5, one-way ANOVA, Tukey’s post hoc analysis).
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shown (Fig. 5C,D). Effects of [D-Arg8]-inotocin and SR49059 at other concentrations (1, 3, 10 and 30 nM) are 
presented in Supplementary Fig. 6. [D-Arg8]-inotocin significantly reduced contraction amplitude by 22.9% 
(Fig. 5C) and showed a clear reduction of area-under-the-curve by 36.6% (Fig. 5D). SR49059 (100 nM) signif-
icantly reduced contraction amplitude and area-under-the-curve by 54.8% (Fig. 5C) and 72.1%, respectively 
(Fig. 5D). Contractions under vasopressin alone however persisted without significant loss of amplitude or 
area-under-the-curve for the duration of the experimental protocol (Fig. 5C–F). [D-Arg8]-inotocin did not have 
any effect on myometrial contractions that were augmented with oxytocin (0.5 nM) (Fig. 5G).
Discussion
The oxytocin/vasopressin GPCR family of receptors and neuropeptide ligands are part of a 600-million-year-old 
signalling system regulating many fundamental functions36. Advances in sequencing, molecular cloning and the 
expression of receptors in several heterologous systems have contributed to a renewed interest in structural and 
functional studies of members of this receptor family. The physiological complexity and therapeutic relevance of 
the oxytocin and vasopressin receptors render this receptor family as one of the most studied GPCRs. Therefore, 
oxytocin/vasopressin receptors represent interesting experimental models to study GPCR function and ligand 
development9. Linking the highly homologous receptor subtypes to their specific physiological and pathological 
functions has been a challenging and tedious process, particularly due to the lack of a complete set of receptor 
subtype-selective ligands9. To address this issue, we have recently proposed a strategy that focusses on the discov-
ery and characterization of oxytocin/vasopressin-like ligands from nature and that takes advantage of the ancient 
character, high homology, conservation and distribution of the oxytocin/vasopressin signalling system through-
out the animal kingdom, including humans9. Adopting this strategy has led to the discovery and characterization 
of an ant inotocin ligand pair in this work, which also formed an ideal template for the development of the novel, 
selective and stable human vasopressin V1a receptor antagonist [D-Arg8]-inotocin. [D-Arg8]-inotocin is not only 
an excellent new research tool as will be discussed in the following paragraphs, but also may serve as a promising 
new starting point for future drug design and development efforts targeting V1aR-related disorders.
Previous mutagenesis studies on the V1aR in combination with vasopressin and its analogues have shown that 
residue 8 of vasopressin contributes to high affinity peptide binding in the V1aR25,37. In the present study, we uti-
lized pharmacological measurements of the ant vasopressin-orthologue inotocin, its [D-Arg8]-inotocin analogue, 
and endogenous human vasopressin in heterologous systems expressing the human OTR, V1aR, V1bR and V2R, 
as well as two evolutionary-related inotocin GPCRs from ants and beetles. In a comparative approach, cell-based 
in vitro data were applied to receptor homology models to explain the observed pharmacological effects.
The engineered peptide ligand [D-Arg8]-inotocin is a potent, stable and competitive V1aR-antagonist with 
a 3,000-fold binding selectivity for the human V1aR over the other three subtypes, OTR, V1bR and V2R. We 
note that the observed partial activation of the human V2R by inotocin and [D-Arg8]-inotocin is likely due 
to direct allosteric agonism, which has been described for other GPCRs previously38–41. The insect-derived 
peptide probe [D-Arg8]-inotocin significantly reduced the contraction amplitude and area-under-the-curve 
in vasopressin-augmented tissue, albeit there were no detectable effects on myometrial contractions that 
were augmented with oxytocin. This effect is in line with the reduction in amplitude of contraction and 
area-under-the-curve with the commercially available small molecule V1aR antagonist SR49059 (relcovaptan)10, 
although [D-Arg8]-inotocin is less potent. From a therapeutic viewpoint, the inhibition of human V1aR and the 
partial activation of V2R receptor isoforms by [D-Arg8]-inotocin, although to date there is no compelling evi-
dence for the expression of V2R receptor subtypes in human uterine tissue, could have synergistic effects leading 
to the reduction in contractility and supporting tocolysis42,43.
To provide a molecular explanation for the interesting pharmacological profile of [D-Arg8]-inotocin, we built 
homology models for the human OT, V1a, V1b and V2 receptors as well as the two evolutionary-related insect 
receptors from ant and beetle to identify the binding site residue positions. To deduce structural requirements 
for the binding of the two nonapeptides inotocin and [D-Arg8]-inotocin, we reasonably assumed – supported by 
radioligand displacement data – that the conserved part of the peptide would engage and occupy the same space 
of the orthosteric receptor binding pocket of the receptors allowing us to obtain novel insights of the molecular 
role of the L- to D-Arg substitution. Our data clearly indicates that the stereochemistry of Arg8 is essential for 
binding to the proposed binding pocket of human OTR, V1aR and V1bR, while [D-Arg8]-inotocin only binds to 
the human V1aR and the two inotocin receptors without detectable affinity to the human V1bR, V2R and OTR. 
Interpretation of the observed pharmacological effects leads to the two hypotheses that either (i) the Arg8/D-Arg8 
side chain interacts with different residues, with the putative interaction partner of Arg8 being conserved in all 
subtypes, while that of D-Arg8 only being present in the inotocin receptors and V1aR, or that (ii) the Arg8/D-Arg8 
side chain interacts with the same position and that a nearby residue(s) hinders the interaction of the D-Arg8 
side chain to the position of importance in three of the human GPCRs. Importantly, the observed effects of the 
Arg8 stereochemistry in inotocin/[D-Arg8]-inotocin does not apply to vasopressin/[D-Arg8]-vasopressin, as the 
first pair shows similar binding affinities in the V1aR (11 and 1.3 nM, Table 1), while previous studies have shown 
~200-fold difference in affinity of the latter peptide pair (4.2 and 781 nM)32,43. While this does not exclude similar 
binding modes for inotocin and vasopressin, it clearly shows different binding modes for [D-Arg8]-inotocin and 
[D-Arg8]-vasopressin and different spatial locations of Arg8 in the binding site. Furthermore, neither vasopressin 
(Table 2), nor the non-selective vasopressin V2R agonist, desmopressin (1-desamino-8-D-arginine-vasopressin; 
dDAVP), activates inotocin receptors (Supplementary Fig. 7).
The binding site alignment does not pinpoint a unique position with an acidic or hydrogen bond-accepting 
residue in the binding site of [D-Arg8]-inotocin binding receptors, thereby weakening hypothesis (i) of different 
interaction partners for the guanidine moiety of Arg8/D-Arg8. Instead, the alignment revealed two positions, 
7×38 and the 4th residue in ECL2 (Ile192 in V1aR), which distinguish the [D-Arg8]-inotocin binding receptors 
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from the non-binding ones. Importantly, these two positions are in proximity of the negatively charged Glu1×35 
and Asp/Glu45×49, respectively, which are conserved within the vasopressin and inotocin receptors, and poten-
tial interaction partners to the side-chain of Arg8/D-Arg8. Residue Glu1×35 is located in the second helical turn 
and Asp/Glu45×49 in ECL2 next to Cys45×50 forming a disulphide bridge to TM3 and hence both positions are 
conserved in structure as well as in sequence. Of note, position 45×49 and 45×50 in ECL2 have been considered 
to be essential for high-affinity agonist binding and receptor activation and to be highly conserved throughout the 
neurohypophyseal hormone receptor subfamily of GPCRs44.
Compared to V1bR, V2R and OTR, where position 7×38 is a methionine, the short side chain residues Ala, 
Ser and Thr occupy this position in V1aR and the two inotocin receptors, respectively. The steric hindrance of the 
longer methionine side chain in combination with the stereochemistry of Arg8/D-Arg8 offers a potential expla-
nation for the lack of [D-Arg8]-inotocin binding to V1bR, V2R and OTR, if Glu1×35 is a key interaction partner 
(Fig. 4B). Arg8 and D-Arg8 could approach the putative salt bridge partner from slightly different directions 
and, while the short side chains allow unhindered access of both, Met7×38 in V1bR, V2R and OTR may sterically 
interfere with D-Arg8 only. Additionally, the structural neighbour, Lys2×65 in V2R (Asp in the other receptors), 
provides a structural explanation for the marked reduction in affinity of inotocin in V2R compared to the other 
receptors (Table 1) likely due to a charge repulsion – an explanation that could also apply if the positively charged 
peptide C-terminus was the interaction partner of Glu1×35. Ile192 in V1aR is a structural neighbour to Asp/
Glu45×49 on the adjacent β -strand and along with Gln and Thr at the two inotocin receptors, is a non-positively 
charged residue. In comparison, this same position holds an arginine in V1bR, V2R and OTR. Arginine in this 
position is likely to form a salt bridge to Asp45×49 in V1bR, V2R and OTR, blocking part of the interaction area 
of the aspartate (Fig. 4C). If the stereochemistry of Arg8/D-Arg8 results in a different location of the guanidine 
moiety relative to the Asp45×49, it is likely that the presence of an arginine in this position may prevent only 
[D-Arg8]-inotocin from forming a salt bridge, thus abolishing or severely impeding binding of this peptide in 
V1bR, V2R and OTR. This hypothesis also puts the Arg8 guanidine of inotocin in the vicinity of the structurally 
neighboring Tyr115(23×50) in V1aR (Fig. 4C), which together with position 45×49 has also been hypothesized to 
interact with the Arg8 side chain of vasopressin37,44. Since both DAVP and dDAVP bind potently to V2R37, but 
[D-Arg8]-inotocin does not bind (Table 1), the observed affinity differences in V1aR, indicates overlapping bind-
ing modes of inotocin and vasopressin, but not of [D-Arg8]-inotocin and [D-Arg8]-vasopressin.
At a more general level, the function of a peptide on a receptor is not as logically reflected in the ligand-receptor 
interactions as the binding affinity, whereas our structural sequence alignment of the receptor binding site may 
indicate which residues are responsible for the pharmacological differences observed from the experimental data. 
Inotocin display ~20-fold higher potency at L. niger vs. the T. castaneum inotocin receptor inspite of similar 
binding affinities (Tables 1 and 2). It is tempting to ascribe this observation to the unique glutamate in position 
45×49 of the L. niger inotocin receptor, which may in general favour activation relative to the aspartate of the 
other receptors and, additionally, activation by the guanidine of inotocin relative to that of [D-Arg8]-inotocin. 
Moreover, this would further support position 45×49 as the crucial interaction partner of the Arg8/D-Arg8 side 
chain and not the alternative Glu1×35, which is conserved in all six receptors.
Another and more clear-cut pharmacological observation is that, in contrast to the agonistic effects of inotocin 
and [D-Arg8]-inotocin on the inotocin receptors (plus inotocin on V1bR), both peptides exert antagonist effects 
on V1aR. The search for sequence differences, which may offer an explanation for this observation, results in only 
two positions, 3×40 and 7×34, that clearly distinguish V1aR from V1bR and the two inotocin receptors. This lack 
of activation is clearly ligand dependent, as the related neuropeptide, vasopressin, potently activates V1aR indi-
cating that the responsible amino acids are one or more of Tyr2, Phe3 and Gln4 in vasopressin, which differ from 
the corresponding positions in inotocin, Leu2, Ile3 and Thr4. Assuming that vasopressin, relative to inotocin, 
forms some additional contacts to V1aR that are responsible for activation, neither Ala139(3×40) nor Ile330(7×34) 
provides an explanation for this fact. However, position 3×40 in the narrow bottom part of the binding site has 
together with 5×50 and 6×44 been shown by the research team of Kobilka45 to form a ‘conserved core triad’ in 
other class A receptors. These three positions are dominantly Ile/Leu/Val, Pro and Phe/Tyr, respectively, and 
rearrange their hydrophobic packing during movement of TM6 and receptor activation. Additionally, the combi-
nation of NMR and mutagenesis experiments showed that increasing the van der Waals contact area by Val-to-Ile 
exchange in position 3×40 of a thermostabilised β 1 adrenoceptor shifts the receptor towards an active state46. 
Considering a similar activation switch in the receptors studied here, we performed in silico exchange of posi-
tions 3×40 and 6×44 in the crystal structure of the active state μ -opioid receptor45 with those of V1bR (Fig. 6A). 
In our V1bR homology model of the inactive state, Tyr290(6×44) and Thr122(3×40) forms an inter-helical hydrogen 
bond (Fig. 6B). However, the movement of TM6 in the active state allows Tyr290(6×44) to form a hydrogen bond 
to the backbone carbonyl of the residue in position 5×461. This position is a so-called helical ‘bulge’ residue, i.e. 
an additional 5th residue in a helical turn33 and, together with the conserved Pro5×50, this changes the normal 
helical hydrogen bonding pattern making the backbone carbonyl accessible to Tyr290(6×44) (Fig. 6A). Assuming 
a conformational change analogous to those observed in the crystal structures45 the conformation of Tyr290(6×44) 
is likely further stabilized by an additional hydrogen bond to Thr122(3×40). Among the receptors studied here, 
only V1aR lacks the hydrogen bonding residue in position 3×40 that potentially stabilizes an active receptor state 
(Fig. 6C). Thus, our data indicates that the lack of this hydrogen bond due to Ala139(3×40) in V1aR results in an 
increased energy barrier of activation, which can explain the different pharmacological actions of inotocin and 
[D-Arg8]-inotocin on V1aR vs. V1bR and the two inotocin receptors. Interestingly, the mouse V1aR does contain a 
serine in position 3×40, which may explain observed pharmacological differences relative to the human receptor47. 
Additionally, mammalian oxytocin receptors have a phenylalanine in position 6×44 (Fig. 6), which also pre-
vents formation of the hydrogen bonding network: this also agrees with the observed lack of activation of the 
human OTR by inotocin, despite the peptide binding. This further implies that vasopressin may have evolved 
to compensate for the increased activation energy barrier, particularly through residues Tyr2, Phe3 and Gln4 
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of the peptide mediating key contacts. This may be a fine example of co-evolution of peptide and receptor, i.e. 
arginine-vasopressin and the human V1aR.
More than 60 years have passed since the discovery, synthesis and characterization of oxytocin and vasopressin, 
yet there still remains a shortage of agonists and antagonists with good selectivity for the four known receptor sub-
types48. The development of antagonists for vasopressin receptors is challenging due to the large degree of structural 
homology within the four receptor subtypes and their inter-species differences. Currently, there are no ligands in 
clinical use with selective antagonist activity for the V1aR over the V1bR and V2R. For this reason, novel strategies 
for ligand discovery and design represent a powerful option and a promising opportunity to outpace and effectively 
tackle this problem. Vasopressin antagonists are valuable pharmacological tools for investigating the pharmacolog-
ical functions of the nonapeptide vasopressin. Previous studies have demonstrated that the carboxy-terminal posi-
tion in vasopressin is a critical structural requirement for receptor activation but not binding49. To guide the rational 
design of novel peptide antagonists based on the moiety of the native ligand, it is necessary to identify conserved and 
non-conserved functional receptor domains involved in receptor binding and activation, such as residue positions 
192 in V1aR, 3×40, 45×49, 6×44 and 7×38 that were described and analyzed in this study.
Figure 6. Putative structure and sequence homology of the conserved core triad. (A) Putative hydrogen 
bonding network (yellow dotted lines) of residues in position 3×40, 5×50 and 6×44 of V1bR (white cartoon and 
sticks) in an active receptor state by in silico amino acid exchange into the active state μ -opioid receptor crystal 
structure (PDB code: 5CM1)45. The hydrogen bond between Tyr6×44 and the backbone carbonyl of position 
5×461 is accomplished by a large movement of TM6 relative to the inactive state. (B) Hydrogen bond between 
Thr3×40 and Tyr6×44 in the inactive state V1bR homology model. (C) Sequence conservation of positions 
3×40, 5×50 and 6×44 in the studied receptors and vasopressin/oxytocin receptors from selected species. 
Interestingly, most V1aRs lack the hydrogen bonding ability in position 3×40 as do the OTRs in position 6×44, 
which according to our model may result in different activation kinetics and thus different pharmacology. The 
consensus sequence, the conservation score from 1–10 by physico-chemical properties72 and “*” indicating 
complete identity is given below the alignment.
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Conclusion
Oxytocin/vasopressin receptors are promising targets for important diseases, including cardiovascular and neu-
rological disorders. Despite extensive efforts there is demand for oxytocin/vasopressin ligands as therapeutics or 
modulators to probe the biological function of individual receptor subtypes. In a novel strategy that is broadly 
applicable to the development of selective ligands for the oxytocin/vasopressin family, we explored the evolutionary 
conservation of this signalling system to discover and subsequently engineer a competitive, subtype-selective and 
stable human V1aR-antagonist. We gained deeper insights into ligand-receptor pharmacology through integrated 
and iterative structure modelling and pharmacological evaluation. In fact, understanding the molecular mechanisms 
responsible for agonist and antagonist binding is critical and the information derived from our study may be useful 
for the rational design of potential therapeutic agents targeting oxytocin/vasopressin receptors. Furthermore, we 
have demonstrated the utility of the engineered inotocin ligand in a translational ex vivo human myometrial con-
tractility study. Therefore, we consider that [D-Arg8]-inotocin has great potential to advance our understanding of 
V1a-receptor physiology and its associated role in disease. Overall, this study establishes proof-of-concept for exploit-
ing insect-derived neuropeptide probes for human ligand development, which may be applied to other GPCRs.
Methods
Transcriptome analysis. For the transcriptome analysis, 96 Lasius niger workers were used from labo-
ratory colonies established at the IST Austria, and reared under a 14 h day (27 °C) – 10 h night (21 °C) cycle. 
Total RNA was extracted from 48 pools of two workers each, using the Maxwell® 16 Research instrument and 
the Maxwell® 16 LEV simplyRNA Tissue Kit (Promega, Mannheim, Germany). After extraction, all 48 sam-
ples were pooled resulting in a single sample with an overall amount of 24 μ g total RNA based on NanoDrop 
measurements (A.V. Grasse, unpubl.). The RNA was sent to Eurofins MWG GmbH (Ebersberg, Germany) for 
quality control, preparation of a 2x normalized, random-primed cDNA library and subsequent sequencing on 
the Illumina HiSeq 2000 platform, applying the 2 × 100 bp paired-end read module. The raw sequence reads were 
checked with FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/, version 0.11.2), filtered and 
trimmed with PRINSEQ lite50 (version 0.20.4) with the following parameters: min_len 40, min_qual_mean 28, 
trim_tail_left 8, trim_tail_right 8, and trim_ns_right 1. To remove all rRNA, SortMeRNA51 (version 1.8) with 
the default eight databases and default parameters was applied. For de-novo transcriptome assembly of the high 
quality mRNA read pairs, Trinity52 (r2013-02-25) was used. The resulting contigs were tested for completeness 
via CEGMA53 (version 2.5). To identify contigs representing the precursor and receptors, a BLAST54 search via 
TBLASTN, in BLAST + (version 2.2.29) against the assembly as database was carried out. Default parameters 
with an e-value cut-off of 1e-4 were used. As query the amino acid sequences of the following inotocin pre-
cursors and receptors were used: Harpegnathos saltator (GenBank accession DAA35079.1, XM_011149198.1, 
XM_011153432.1), Atta cephalotes (DAA35080, XP_012061245.1), Camponothus floridanus21, Acromyrmex 
echinatior (XM_011067026.1, EGI60623.1), Solenopsis invicta (XM_011161311) and Pogonomyrmex barbatus 
(XM_011641193, XM_011641194.1, XM_011641195.1). The multiple alignments of the blast-hits with the query 
sequences were calculated with Clustalw55 and MAFFT56. For the phylogenetic reconstruction of described recep-
tors versus the best blast hits, we aligned 30 well described receptors with the top blast hits based on e-value, with 
Clustalw. The phylogenetic tree was then calculated via maximum likelihood phylogenetic reconstruction with 
RAxML (version 8.2.4)57, with the PROTGAMMABLOSUM62 model and 100 bootstrap replicates. For re-root-
ing and visualization of the phylogenetic tree we used Dendroscope58.
cDNA cloning of the inotocin precursor. The full length precursor was obtained via Rapid 
Amplification of 3′ cDNA Ends (3′ RACE) technology. RNA of whole workers from laboratory colonies was 
extracted using Quick-RNATM MiniPrep kit (Zymo Research, Irvine, USA) and reverse transcription was 
done using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, USA) and 
polyT primer 5′ -GGCCACGCGTCGACTAGTACTTTTTTTTTTTTTTTTT-3′ . First PCR was performed 
using Phusion Hot Start II polymerase (Thermofisher Scientific, Waltham, USA) and primers polyT-end 
CTACTACTACTAGGCCACGCGTCGACTAGTAC and FW ATGCTAAAGAAGCTTGTCATTTTTGCGAG. 
Nested PCR was carried out using the first PCR product as template with a FW-nested primer 
5′ -AATTTTCCTGAGTTACGCTTGTTTGATTAC-3′ and the polyT-end primer. PCR fragments (~500 bp) were 
extracted, purified using GeneJET Gel Extraction kit (Thermofisher Scientific, Waltham, USA) and sequenced 
at LGC Genomics (Berlin, Germany) using the FW-nested primer. After determining the unknown 3′ sequence, 
one more PCR was performed using FW and Seq-Rev AAGTTGAAACATCAAAGTAATAAGCAAAAACTATG 
primers and cDNA as template. The obtained PCR fragment (full length inotocin precursor) was directly 
sequenced using the Seq-Rev primer to obtain the full length reading frame of the precursor sequence.
cDNA cloning of inotocin receptor. The cDNA of the ant inotocin receptor was obtained by reverse 
transcription using the OneStep RT-PCR kit (Qiagen, Venlo, The Netherlands) and RNA isolated from 
L. niger as a template; the following primers were used: 5′ -ATGTCGTATGACTCGAATACGTC-3′ (sense) and 
5′ -TCAGCCGAATATCTTTGAACTCG-3′ (antisense). Blunt end ligation of the PCR product with pJET1.2 vec-
tor was carried out at 4 °C (Clone Jet PCR cloning kit, Thermo Scientific Waltham, USA). Successful cloning was 
determined by digest using restriction endonuclease BglII (Thermo Scientific, Waltham, USA) and DNA sequenc-
ing of the plasmid containing the amplification product corresponding to the full length receptor (Microsynth AG, 
Balgach, Switzerland). For cellular expression, the receptor cDNA was cloned into the pEGFP-N1 vector at the 
restriction sites EcoRI and KpnI using the primers 5′ -ATTCGAGAATTCATGTCGTATGACTCGAATACG-3′ 
(sense) and 5′ -ACGCACGGTACCGTGCCGAATATCTTTGAACTCGCAAGTCGTGAAATTCTAG-3′  
(antisense). This resulted in a plasmid encoding the L. niger inotocin receptor together with 
a C-terminal  GFP fusion protein.  The cDNA pXN-INTR from T. castaneum  was kindly 
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provided by Yoonseong Park (Department of Entomology, Kansas State University59,60). Similarly, the bee-
tle inotocin receptor was cloned into pEGFP-N1 for cellular expression utilizing the KpnI and AgeI restric-
tion sites and the primers 5′ -ATTGGAGGTACCATGGACATCTCTGAGAACTCTACG-3′ (sense) and 
5′ - ATCGTCACGACGACCACCCCACCGGTCGCCACCATGGTG-3′ (antisense). Human receptor constructs 
encoding for the OTR, V1aR, V1bR and V2R were prepared and used as reported previously35.
Database deposition. Nucleotide sequences corresponding to the coding sequences of the L. niger ino-
tocin prepro-hormone and receptor were deposited in GenBank under the accession numbers KX266837 and 
KX266836, respectively. The raw sequence read files were deposited under the bioproject PRJNA352917; the 
sequence reads can be found in the short read archive: accessions SRR5007208 and SRR5007267.
Peptide synthesis. Peptides were assembled manually via Boc-SPPS using the HBTU-mediated in situ neu-
tralization protocol61,62. After HF cleavage63, the crude peptides were purified by preparative RP-HPLC (Vydac C18 
column, 300 Å, 10 μ m, 250 × 21.2 mm) using a linear gradient of 0–50% B (solvent A, H2O/0.05% TFA; solvent B, 
90% CH3CN/10% H2O/0.043% TFA) in 50 min at 8 mL min−1 while monitoring UV absorbance at 226 nm. Air 
oxidation was carried out in 0.1 M NH4HCO3 buffer at 25 °C and a peptide concentration of 100 μ M. Oxidation, 
deprotection and degree of purification were monitored by mass spectrometry (MS) on a LCT-TOF mass spec-
trometer equipped with an electro-spray ionization source (ESI), by analytical RP-HPLC using a Vydac (Grace, 
Epping Vic, Australia) C18 column (300 Å, 5 μ m, 250 × 4.6 mm) at 214 nm and by ESI-LC-MS on a Phenomenex 
(Torrence, USA) Jupiter LC-MS C18 column (90 Å, 5 μ m, 250 × 2 mm) on a SCIEX QSTAR Pulsar QqTOF mass 
spectrometer (Applied Biosystems, Carlsbad, USA) equipped with an atmospheric pressure ionization source, 
running a linear gradient 0–50% B over 50 min with a flow rate of 1 mL min−1 for RP-HPLC and 200 μ L min−1 for 
LC-MS. The synthesized peptides were of > 95% purity determined by analytical RP-HPLC monitored at 214 nm.
[3H] inotocin synthesis. Fmoc-L-[4,5-3H] leucine obtained by catalytic tritiation of Fmoc-
4,5-dehydro-L-leucine (S.A. =  112.6 Ci mmol−1) was added to the protected precursor peptide 
(CLITNCPRG-NH2) on PAL resin (Bachem, Bubendorf, Switzerland) using a standardised Fmoc protocol64. 
After the addition of a terminal cysteine residue the peptide was cleaved from the resin, deprotected and the 
disulfide bond was formed by bubbling air through the 0.1 M buffer solution (AcONH4, pH = 8.4) of the peptide. 
After radio-HPLC purification the [3H] inotocin (C[4,5-3H]LITNCPGR-NH2, radiochemical purity > 99.9%; spe-
cific activity = 55.7 Ci mmol−1) was prepared in a solution of H2O:EtOH 4:1 (v/v) at 1 mCi mL−1.
Cell culture and transient receptor expression. Chinese Hamster Ovary cells (CHO) were cultured 
in Ham’s F12 media supplemented with 10% fetal bovine serum (FBS), 1% PenStrep (all from Sigma-Aldrich, 
Munich, Germany) and grown in a humidified atmosphere of 37 °C, 5% CO2 and passaged on average twice per 
week. CHO cells were used for expression of inotocin receptor (L. niger, T. castaneum). Cell transfections were 
carried out with 10 μ g of plasmid using Lipofectamine LTX (Life Technologies, Invitrogen, Carlsbad, USA) for 
invertebrate receptors. For the expression of human OTR, V1aR, V1bR and V2R, HEK293 cells were transfected 
using jetPRIME (Polyplus Transfections, Illkirch-Graffenstaden, France)35. Cells were maintained in DMEM (GE 
Healthcare Hy Clone™ , Logan, USA) supplemented with 10% FBS and 1% PenStrep. Fluorescence and receptor 
expression was confirmed via epifluorescence microscopy 24 h post-transfection.
Radioligand binding assays. Binding experiments were performed on transient receptor expressing 
membrane preparations (10–50 μ g per assay), which were incubated with radioligand and peptide in 100 μ L 
buffer containing 9 mM MgCl2, 25 mM Hepes, 0.15 mM bacitracin, 0.0015% (w/v) apoprotinin and 0.1% (w/v) 
bovine serum albumin. [Tyrosyl-2,6-3H]oxytocin, 47.4 Ci mmol−1 and [[phenylalanyl-3,4,5-3H]vasopressin, 
61.2 Ci mmol−1 were from PerkinElmer Life Sciences, Warwick, USA; synthesis of [3H] inotocin was described 
above. Displacement of radioactive ligand was assayed in the presence of logarithmically-spaced concentrations 
of competing ligand or control oxytocin/vasopressin peptides. After 2 h at 20 °C, the reaction was terminated 
by rapid filtration over glass fibre filters (102 × 258 mm) (Filtermat A Wallac) previously soaked for 5 min in 
polyethylenimine 0.3% (v/v) in TRIS buffer (25 mM), to minimize unspecific binding. Unbound ligands were 
washed off (Skatron Cell Harvester). Displacement of radioactive ligand was assayed in the presence of saturating 
concentrations (10 μ M) of oxytocin, vasopressin or inotocin, respectively, to determine non-specific binding. 
For the displacement at the human OTR, V1aR, V1bR and V2R the normalization to 100% refers on average to 
0.49, 1.4, 0.36, 1.1 pmoles of ligand bound per milligram of membrane for human OTR, V1aR, V1bR and V2R, 
respectively. Bindings of [3H] AVP and [3H] OT were performed with a radioligand concentration dependent 
on the Kd of each receptor subtype (1.5, 0.6, 0.1 and 1.2 nM for OTR, V1aR, V1bR and V2R). Membranes (30–50 μ 
g) expressing human OTR, V1aR, V1bR and V2R, were assayed for displacement with an excess of inotocin or 
[D-Arg8]-inotocin, and vasopressin or oxytocin (10−11 to 10−5 M) as positive control for each receptor (n ≥ 3, 
except where otherwise stated). For the displacement at the insect receptors the normalization to 100% refers 
on average to 0.65 and 0.69 pmoles of ligand bound per milligram of membrane for inotocin receptor from L. 
niger and T. castaneum, respectively. Bindings of [3H] inotocin to membranes (10 μ g) expressing INTR from L. 
niger, or [3H] inotocin to membranes (10 μ g) expressing INTR from T. castaneum, respectively, were assayed for 
displacement with an excess of inotocin (10−11 to 10−5 M) (n ≥ 3, except where otherwise stated). Kd values of 
inotocin receptors were determined from saturation binding experiments to be 0.9 nM (L. niger) and 2.7 nM (T. 
castaneum). Specific binding was calculated by subtracting the non-specific binding from the total binding. IC50 
values were obtained by fitting the data to a three-parameter logistic Hill equation. Inhibition constants (Ki) were 
calculated from IC50 using the method by Cheng and Prusoff65.
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Functional receptor activation assays. Activation of Gq-signalling via the human V1aR, V1bR and OTR, 
as well as the insect INTR was measured by inositol-1-phosphate (IP1) quantification using an IP1 Tb kit (Cisbio, 
Codolet, France). Transfected cells were seeded in 96 well-plates, with a cell density of 104 cells per well. Cell culture 
media was removed from the wells after 6 h and 70 μ L of peptide of interest, prepared in IP1 1X Stimulation Buffer 
at the desired concentrations, was added. Samples were measured in technical triplicates. After 1 h incubation at 
37 °C, 15 μ L of IP1-d2 was added, following the same volume of Ab-cryptate. After 1 h of incubation, activation was 
GPCR quantified via fluorescence measurement (SynergieH4, Biotek Instruments, Winooski, USA) using the ratio 
665/620 nm. Activation of Gs-signalling via the human V2R was measured using a luciferase reporter assay. HEK293 
transiently expressing V2R were co-transfected with the pGL4.29 [luc2P/CRE/Hygro] (Promega, Mannheim, 
Germany) plasmid. After ligand stimulation, 6 h incubation at 37 °C, medium was removed and cells were kept at − 
80 °C for at least 12 h before lysis. The measured luciferase counts (SynergieH4) were corrected using the fluorescent 
intensity per well and normalized to the maximum activation of oxytocin/vasopressin peptides. For cell-based func-
tional assays (luciferase and IP1), subtraction of the negative control (stimulation buffer) was applied to all data set. 
The normalization was performed to the highest value of the positive control from at least 4 independent experiments. 
Data were fitted using GraphPad Prism 5.0 with an equation for non-linear regression (sigmoidal, slope fit of 1). 
Values are reported as mean ± SEM. For Schild regression analysis, each concentration-ratio (r) was calculated as 
the agonist EC50 in the presence of a respective concentration of [D-Arg8]-inotocin by the EC50 of the agonist alone. 
The logarithm of the concentration-ratio (r-1) has been plotted vs. the logarithm of the respective concentration of 
[D-Arg8]-inotocin to obtain the pA2 value, which is defined as the negative logarithm of the molar concentration of 
the antagonist producing a two-fold shift in the agonist concentration-response curve (r = 2).
GPCR homology modelling and in silico analysis. Template selection for the homology modelling was 
performed in GPCRdb66 using the human V1aR sequence as the query and selecting the μ -opioid31 and orexin32 
crystal structures downloaded from the Protein Data Bank (rcsb.org/pdb)67 as templates. Sequences of the four 
human receptors and the beetle receptor were downloaded from the UniProt Knowledgebase uniprot.org68 (V1aR: 
P37288, V1bR: P47901, V2R: P30518 and OTR: P30559; T. castaneum D6WPA3), and the ant inotocin receptors 
was obtained by transcriptome mining and confirmed by PCR and sequencing. Multiple sequence alignment 
between V1aR, V1bR, V2R, OTR and the two invertebrate templates was created by manually adjusting the struc-
ture based sequence alignment from GPCRdb and adding the two inotocin receptors using ClustalX55. Homology 
models were constructed in MODELLER69, version 9.15; since they are only used for comparing structural posi-
tions, the optimization was disabled by using the “very_fast” keyword. The residues of the inter-helical binding 
site was defined in PyMOL (The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC.) by the 
residues comprising the van der Waal surface within the helical bundle and the surface of the ECL2 nearest to the 
cavity, thus extracted from the overall sequence alignment. The inotocin and [D-Arg8]-inotocin fragments used 
to illustrate the selectivity hypotheses were built and manually inserted into the binding site in Maestro (Maestro, 
version 10.3, Schrödinger, LLC, New York, NY, 2015). In silico amino acid exchange was performed using the 
mutagenesis wizard in PyMOL on the μ -opioid active state crystal structure45 downloaded from the PDB.
Serum stability assays. Serum stability was tested as described previously70. Briefly, serum was obtained 
prepared from human blood (self-donor), allowed to coagulate for 2 h at 23 °C and centrifuged at 12,000 × g for 
10 min. Peptides (100 μ M) were incubated in serum for 2, 4, 6, 8, 10 and 24 h at 37 °C. To evaluate peptide stability, 
aliquots (25 μ M) were analysed via RP-HPLC (UltiMate 3000, Thermo Scientific Dionex, Vienna, Austria) on 
a C18 column (Phenomenex Kinetex, Aschaffenburg, Germany) with a 3% gradient using 0.1% (v/v) TFA and 
90/10/0.1% (v/v/v) acetonitrile/H2O/TFA as eluents. Half-life (t1/2) of peptides was calculated using non-linear 
regression analysis using Graph Pad Prism.
Human myometrial contractility assays. Biopsies of human myometrium were obtained during 
pre-labour elective Caesarean Section (CS) delivery at term gestation (38–41 weeks) at Liverpool Women’s 
Hospital NHS Foundation Trust, Liverpool UK. At surgery, a biopsy measuring approx. 1 cm3 was cut from the 
upper lip of the lower uterine incision site and placed into Hanks Balanced Salt solution at 4 °C. All women 
provided written informed consent and ethical approval was sought and granted by the Local Research Ethics 
Committee (REC Ref: 10/H1002/49) and by the Research and Development Director of Liverpool Women’s NHS 
Foundation Trust, Liverpool, UK. Multiple strips were dissected and measured as previously described35,71. Data 
were analysed using OriginPro9.0 Software (OriginLab, Northampton, USA). Contractile activity was measured 
by calculation of the integral area-under-the-tension-curve (AUC, arbitrary units) and mean maximum ampli-
tude of contraction (expressed in mN). Contractile activity in the final 25 min of vasopressin or oxytocin expo-
sure, preceding the addition of the first concentration of [D-Arg8]-inotocin or SR49059 was taken as control 
activity. The activity under each concentration (or time period equivalent for vasopressin) were similarly calcu-
lated and expressed as a percentage of this control period (i.e. control activity is equal to 100%). Values represent 
the mean ± SEM where ‘n’ is the number of samples, each representing a different woman. All methods were 
performed in accordance with the relevant guidelines and regulations.
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